D Arthur

First results of the rwe prospective study TEC care (IFM 2023-01) evaluating teclistamab in triple-class exposed relapsed refractory multiple myeloma patients.

Aurore Perrot, Cyrille Hulin, Stéphanie Harel, Veronique Vitry et autres

Abstract Introduction Teclistamab was the first approved BCMAxCD3 bispecific antibody for the treatment of patients with relapsed refractory multiple myeloma (RRMM) previously exposed to a proteasome inhibitor (PI), an immunomodulatory drug (IMiD), and an anti-CD38 antibody based on the data from MajesTEC-1 …

fr, es (code pays fourni par la source)

Impact of 7-day versus standard venetoclax exposure in combination with azacitidine in frontline AML settings: A real-world analysis from the venaura retrospective multicenter study

Gaspar Aspas Requena, Pedro Chorão, Samy Chraïbi, Urbain Tauveron-Jalenques et autres

Abstract Background Azacitidine (AZA) plus venetoclax (VEN) is the standard first-line treatment for patients with acute myeloid leukemia (AML) ineligible for intensive chemotherapy (IC). While current recommendations favor continuous ≥21-day VEN cycles, real-world adaptations using shorter schedules are common, aiming to reduce …

fr, es (code pays fourni par la source)

Allogeneic Hematopoietic Cell Transplantation in Newly Diagnosed and Relapse/Refractory AML Patients Post Venetoclax-Azacitidine Treatment: A Multicenter Real-Life Analysis By the French Auraml Group

Urbain Tauveron-Jalenques, Zofia Gross, Martin Carré, Emmanuelle Tavernier et autres

Allogeneic hematopoietic stem cell transplantation (ASCT) remains the most effective curative treatment for patients with high-risk acute myeloid leukemia (AML). However, patients ineligible for intensive chemotherapy (IC) due to age or comorbidities have typically not been viable candidates. The therapeutic landscape of …

fr, es (code pays fourni par la source)

Real World Use of Azacitidine and Venetoclax in Acute Myeloid Leukemia in Frontline and Relapse/Refractory Settings: A Multicentric Study from French Auraml Group

Zofia Gross, Urbain Tauveron-Jalenques, Gaspar Aspas Requena, Martin Carré et autres

Azacytidine and venetoclax combination regimen (AZA/VEN) is the standard of care in frontline acute myeloid leukemia (AML) settings for unfit to intensive chemotherapy patients. However, AZA/VEN is also associated with an increased hematological toxicity compared to azacytidine alone. In this context, alternative …

fr (code pays fourni par la source)

PCN300 SYSTEMATIC LITERATURE REVIEW OF PATIENT-REPORTED OUTCOME MEASURES USED IN MANTLE CELL LYMPHOMA

Kurochkin MIu, Swetha Challagulla, D Arthur, Jutta K. Neuenburg et autres

us (code pays fourni par la source)

PCN144 IBRUTINIB TREATMENT IS ASSOCIATED WITH LOWER HEALTHCARE RESOURCE UTILIZATION AND TOTAL COST REDUCTION COMPARED TO CHEMOIMMUNOTHERAPY IN PATIENTS WITH MANTLE CELL LYMPHOMA

Reethi Iyengar, Elisabetta Malangone-Monaco, C. Sugg, D Arthur et autres

us (code pays fourni par la source)

Direct in vivo evidence for increased proliferation of CLL cells in lymph nodes compared to bone marrow and peripheral blood

Thomas M. Herndon, S-S Chen, Nakhle S. Saba, Janet Valdez et autres

us (code pays fourni par la source)

Clinical features predict responsiveness to imatinib in platelet-derived growth factor receptor-alpha-negative hypereosinophilic syndrome

Paneez Khoury, Ronan Desmond, Andrea Pabon, Nicole Holland‐Thomas et autres

BACKGROUND: With the exception of the presence of the FIP1L1-PDGFRA fusion gene, little is known about predictors of imatinib response in clinically-defined hypereosinophilic syndrome (HES). METHODS: Subjects with FIP1L1-PDGFRA-myeloid neoplasm (FP; n =12), PDGFRA-negative HES with ≥4 criteria suggestive of a myeloid …

us, ie (code pays fourni par la source)

Myelodysplasia in autosomal dominant and sporadic monocytopenia immunodeficiency syndrome: diagnostic features and clinical implications

Katherine R. Calvo, Donald C. Vinh, I. Maric, Wei Wang et autres

A novel, genetic immunodeficiency syndrome has been recently described, herein termed "MonoMAC". It is characterized by severe circulating monocytopenia, NK- and B-lymphocytopenia, severe infections with M. avium complex (MAC), and risk of progression to myelodysplasia/acute myelogenous leukemia. Detailed bone marrow analyses performed …

us (code pays fourni par la source)

Activity of imatinib in systemic mastocytosis with chronic basophilic leukemia and a PRKG2-PDGFRB fusion

Idoya Lahortiga, Cem Akin, Jan Cools, Todd M. Wilson et autres

BACKGROUND: Translocations involving region 5q31-32 (PDGFRB) have been reported in a variety of myeloproliferative diseases and are often associated with significant peripheral eosinophilia. We report an unusual case of a patient presenting with peripheral basophilia and systemic mastocytosis in whom cytogenetic analysis …

be, us, tw (code pays fourni par la source)

Long-Term Outcome and Prognostic Factors in Children’s Cancer Group Study 2891 for Children and Adolescents with Previously Untreated Acute Myeloid Leukemia and Myelodysplastic Syndrome

Beverly J. Lange, Franklin O. Smith, Nathan L. Kobrinsky, Jonathan D. Buckley et autres

us (code pays fourni par la source)

Frequency of prolonged remission duration after high-dose cytarabine intensification in acute myeloid leukemia varies by cytogenetic subtype.

Clara D. Bloomfield, David Lawrence, John C. Byrd, Andrew J. Carroll et autres

Advances in the treatment of acute myeloid leukemia (AML) have occurred with the introduction of new therapies including high-dose cytarabine and the identification of powerful prognostic factors such as cytogenetics that predict for long-term outcome. To date, the prognostic impact of cytarabine …

us (code pays fourni par la source)